GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMA) » Definitions » Interest Coverage

Dermata Therapeutics (Dermata Therapeutics) Interest Coverage : No Debt (1) (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Dermata Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-3.20 Mil. Dermata Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Dermata Therapeutics has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Dermata Therapeutics Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Dermata Therapeutics's Interest Coverage or its related term are showing as below:

DRMA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


DRMA's Interest Coverage is ranked better than
99.42% of 345 companies
in the Biotechnology industry
Industry Median: 144.99 vs DRMA: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Dermata Therapeutics Interest Coverage Historical Data

The historical data trend for Dermata Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Dermata Therapeutics Interest Coverage Chart

Dermata Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
- - - - No Debt

Dermata Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison of Dermata Therapeutics's Interest Coverage

For the Biotechnology subindustry, Dermata Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermata Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermata Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Dermata Therapeutics's Interest Coverage falls into.



Dermata Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Dermata Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Dermata Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-8.04 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Dermata Therapeutics had no debt (1).

Dermata Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Dermata Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-3.20 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Dermata Therapeutics had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Dermata Therapeutics  (NAS:DRMA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Dermata Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermata Therapeutics (Dermata Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
Executives
Brittany Bradrick director C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Gerald T Proehl 10 percent owner, officer: Pres., CEO and Chairman
Van Hoose Kyri K. officer: Chief Financial Officer C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
David F Hale director 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Steven J Mento director C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Wendell Wierenga director C/O CIPHERGEN BIOSYSTEMS INC, 6611 DUMBARTON CIRCLE, FREMONT CA 94555
Kathleen D. Scott director C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Thomas Insley officer: Chief Financial Officer SKINMEDICA, INC., 5909 SEA LION PLACE, SUITE H, CARLSBAD CA 92010
Bedoya-toro Munera Maria E officer: Senior VP 10590 WEST OCEAN AIR DRIVE, SUITE 200, SAN DIEGO CA 92130
Andrew Seth Sandler director 1301 2ND AVE, SEATTLE WA 98101
Christopher J. Nardo officer: Senior VP, Development C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Proehl Investment Ventures Llc 10 percent owner C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #332, SAN DIEGO CA 92130